EGFR and adenocarcinoma: Another clinical trial which recruited 1,217 East Asian with adenocarcinoma histology, never or light smoke randomized to receive the EGFR inhibitor gefitinib or carboplatin plus paclitaxel (CP) demonstrated that superior progression free survival and overall response rate occurred in the gefitinib group compared with CP but the overall survival was similar [42].